Work

Phase 1/2 dose escalation study of NUV-422, a potent inhibitor of cyclin-dependent kinases 2, 4, and 6, in recurrent or refractory (r/r) high-grade gliomas (HGG) and solid tumors.

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.tps3173

Authors: Patrick Y. Wen, Jordi Rodon Ahnert, John D. Powderly, Howard Colman, Shannon L. Matheny, Anthony A. Golsorkhi, Teeru Bihani, Yan Zhang, Thomas Joseph Kaley

Institutions: Harvard University, Dana-Farber Brigham Cancer Center, The University of Texas MD Anderson Cancer Center, Carolina BioOncology Institute, University of Utah, Huntsman Cancer Institute, Genentech, Radius Health (United States), Memorial Sloan Kettering Cancer Center

Language: English

Topic: Glioma Diagnosis and Treatment

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4286298043

Cites:

Cited by: 4

Related to: 10